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Abstract 19 
GII.4 noroviruses are known to rapidly evolve, with the emergence of a new 20 
primary strain every 2-4 years as herd immunity to the previously-circulating 21 
strain is overcome.  Because viral genetic diversity is higher in chronic as 22 
compared to acute infection, chronically-infected immunocompromised people 23 
have been hypothesized as a potential source for new epidemic GII.4 strains.  24 
However, while some capsid protein residues are under positive selection and 25 
undergo patterned changes in sequence variation over time, the relationships 26 
between genetic variation and antigenic variation remains unknown.  Based on 27 
previously-published GII.4 strains from a chronically-infected individual, we 28 
synthetically reconstructed VLPs representing an early and late isolates from a 29 
small bowel transplant patient chronically infected with norovirus, as well as the 30 
parental GII.4-2006b strain.  We demonstrate that intra-host GII.4 evolution 31 
results in the emergence of antigenically distinct strains over time, comparable to 32 
the variation noted between chronologically predominant GII.4 strains GII.4-33 
2006b and GII.4-2009.  Our data suggest that in some individuals the evolution 34 
that occurs during a chronic norovirus infection overlaps with changing antigenic 35 
epitopes that are associated with successive outbreak strains and may select for 36 
isolates that are potentially able to escape herd immunity from earlier isolates.   37 
Importance 38 
Noroviruses are agents of gastrointestinal illness, infecting an estimated 21 39 
million people per year in the United States alone.  In healthy individuals, 40 
symptomatic infection typically resolves within 24-48 hours. However, symptoms 41 
may persist years in immunocompromised individuals, and development of 42 
successful treatments for these patients is a continued challenge.  This work is 43 
relevant to the design of successful norovirus therapeutics for chronically infected 44 
patients, provides support for previous assertions that chronically infected 45 
individuals may serve as reservoirs for new, antigenically unique emergent 46 
strains, and furthers our understanding of GII.4 norovirus immune-driven 47 
molecular evolution. 48 
49 
Introduction 50 
Noroviruses are the leading cause of gastrointestinal illness worldwide. 51 
While typically an acute disease, norovirus infections can be serious in the 52 
young, old, and immunocompromised, as these groups are at risk for more 53 
severe disease and death (1-3). Norovirus is spread rapidly in environments 54 
where people are found in close proximity including schools and daycares, 55 
nursing homes, cruise ships, and hospitals.  Importantly, hospital outbreaks can 56 
result in significant economic damage, with direct and indirect costs from a single 57 
outbreak reaching $650,000 (4). 58 
Noroviruses are members of the Caliciviridae family and contain a ~7.5 kb 59 
single stranded, positive polarity RNA genome.  They are divided into 5 60 
genogroups; genogroups I and II are responsible for the majority of human 61 
disease and are further subdivided into at least 9 and 22 genotypes, respectively 62 
(5).  The human norovirus genome encodes three open reading frames: the non-63 
structural proteins, the ORF2 major capsid protein (VP1), and the ORF3  minor 64 
capsid protein (VP2) (6).  VP1 is further divided into the shell (S) and protruding 65 
(P) domains, with the P domain is comprised of the P1 and P2 subdomains (6). 66 
Phylogenetic studies indicate that the P2 subdomain is the most variable region 67 
of the norovirus genome (7, 8).  The P2 subdomain is also the most surface 68 
exposed region of the norovirus capsid, interacting with antibodies and 69 
histoblood group antigens, which serve as binding ligands and putative receptors 70 
for human norovirus docking and entry.   71 
GII.4 strains cause over 70% of all norovirus outbreaks (9) and epidemic 72 
outbreaks occur every 2-4 years involving a new antigenically distinct strain (7, 73 
10).  Studies of antigenic variation in GII.4 norovirus have shown that the P2 74 
region is involved in strain specific antibody recognition (7, 11, 12), and contains 75 
at least three blockade (potential neutralization) epitopes (13-15).  In epidemic 76 
strains, genetic variation in P2 is linked to antigenic changes over time, indicating 77 
that molecular evolution in the P2 subdomain is likely driven by escape from 78 
human herd immunity (12-17). 79 
Noroviruses typically cause acute infection in healthy individuals, resulting 80 
in symptomatic infection for 24-48 hours followed by viral shedding for two to four 81 
weeks (18, 19). However, some immunocompromised individuals such as 82 
transplant patients on immunosuppressive drugs, those with primary 83 
immunodeficiencies, cancer patients undergoing chemotherapy, and those with 84 
HIV may develop chronic norovirus infection.  Symptomatic infection and viral 85 
shedding in these patients can persist from weeks to years (20-25) and can 86 
result in medical issues such as dehydration and nutrient deficiencies (26), 87 
making development of treatment options for these patients an important priority.  88 
Unfortunately, there are no approved therapeutics or vaccines for controlling 89 
norovirus infections.  Attempted methods to control chronic infection have 90 
included treatment with drugs effective against other diarrheal diseases (27), 91 
adjustment of immunosuppressive drug type or dosage (28), and oral or enteral 92 
administration of human IgG (29-32).  Although reduction in immunosuppression 93 
coupled with IgG administration has shown promise for some transplant patients, 94 
IgG therapy has failed in other studies, and reduction of immunosuppression is 95 
not always possible. 96 
Existing studies provide a basis to investigate important questions about 97 
chronic norovirus infection.  Although unconfirmed, one recent hypothesis is that 98 
chronically infected norovirus patients may be important sources of infection both 99 
in healthcare settings (33) and as potential reservoirs for new emergent GII.4 100 
norovirus strains (20, 23, 25).  Although the fitness and the infectivity of 101 
chronically shed virus is currently unknown, potential accounts of chronic 102 
norovirus shedders involved in hospital outbreaks and transmission of virus to 103 
both immunocompromised and immunocompetent individuals have been 104 
documented  (21, 33, 34). 105 
Virus capsid sequence and phylogenetic data from chronically infected 106 
patients have found substantial genetic variation over the course of infection in 107 
many, but not all, patients (22, 23, 35). Siebenga et al. found that capsid 108 
mutation rate was linked to immune impairment, suggesting that immune-driven 109 
selection drives evolution in the capsid during chronic infection (35), and explains 110 
differences in evolution depending on level of immunosuppression. Additional 111 
studies have corroborated a role for intra-host immune driven selection by 112 
demonstrating that virus isolated from chronically-infected patients undergoes 113 
positive selection and exhibits higher genetic diversity in the capsid protein than 114 
virus from acutely infected individuals (23, 25). In some chronically infected 115 
patients with GII.4 strain infections, many of the changes occur in blockade 116 
epitopes, areas of known or predicted antigenic importance but antigenic 117 
comparisons have not been performed (13-15, 22, 35).  118 
In this manuscript, we compare and contrast the antigenic differences 119 
using a panel of polyclonal and monoclonal antibodies and time-ordered VLPs 120 
derived from early (day 1—P.D1) and late (day 302—P.D302) capsid protein 121 
amino acid sequences from a chronically infected immunocompromised patient 122 
(23). Our data demonstrate significant antigenic differences between intra-host 123 
variants that mirrors the degree of variation seen in major successive norovirus 124 
strains, suggesting that chronic norovirus infections can evolve antigenically 125 
unique variants with the potential to seed future norovirus outbreaks.   126 
127 
Methods  128 
Sequences and Structural Homology Models 129 
GenBank (NCBI sequence database) sequences used in this study were 130 
JQ478409.1 (GII.4-2006b) (15), JQ417309 (P_04.2009 or P.D1) (23), JQ417327 131 
(P_02.2010 or P.D302) (23), JN595867.1 (GII.4-2009) (15), and JX459908.1 132 
(GII.4-2012) (36), and the VA387 crystal structure is available from the RCSB 133 
Protein Data Bank: identifier 2OBT (37).  We refer to originally-named P_04.2009 134 
as P.D1 and P_02.2010 as P.D302 for simplicity throughout the manuscript. 135 
Homology models of these sequences were constructed using Modeller (Max-136 
Planck Institutue for Developmental Biology) and modeled in PyMOL. 137 
 138 
Production of VRPs. Virus replicon particles (VRPs) encoding the norovirus 139 
major capsid gene were produced as previously described (38). Briefly, 140 
expression vector pVR21 encodes the VEE genome with the VEE structural 141 
genes replaced with a commercially synthesized norovirus ORF2 gene 142 
(BioBasic) behind the 26S promoter. The VEE-norovirus ORF2 construct and two 143 
separate plasmids expressing either the VEE 3526 E1 and E2 glycoproteins or 144 
VEE 3526 capsid protein were used to make RNA. RNA from all three constructs 145 
was electroporated into BHK cells, and 48 hours later VRPs were harvested and 146 
purified by high speed centrifugation. VRP titers were determined by counting 147 
fluorescent cells detected with FITC-labeled antibody. VLP production from VRPs 148 
and structural integrity was confirmed by EM. 149 
 150 
Production of VLPs. VLPs were produced as previously described (13, 15). 151 
Briefly, commercially synthesized norovirus ORF2 (BioBasic) from chronically 152 
infected patient sequence or outbreak strain sequence was cloned into 153 
expression vector pVR21 behind the 26S promotor, and genome length RNAs 154 
were synthesized in vitro using T7 RNA polymerase.  RNA from the VEE-ORF2 155 
construct and helper RNAs was electroporated into BHK cells, and 24 hours later 156 
VLPs were harvested and purified by high speed centrifugation.  VLP 157 
concentration was determined by BCA Protein Assay (Pierce), and structural 158 
integrity was confirmed for all VLPs by EM. 159 
 160 
HBGA Binding Assay.  HBGA assays were performed as previously described 161 
(7).  Briefly, Avidin coated plates (Pierce) were coated with 10 ug/mL synthetic 162 
biotinylated HBGAs (GlycoTech), followed by addition of 2 ug/mL VLPs.  HBGA 163 
binding was detected by strain specific mouse polyclonal sera followed by anti-164 
mouse IgG-HRP (GE Healthcare) and then One-Step Ultra TMB HRP substrate.  165 
Positive reactivity for each HBGA is defined as an OD 450 nm signal above or 166 
equal to 3X the background binding (background range 0.049-0.066) after 167 
background subtraction. 168 
 169 
EIAs. Reactivity with mouse and human mAbs was determined by enzyme-linked 170 
immunoassay (EIA). Plates were coated with 0.5 μg/ml VLP in PBS, and then 171 
two-fold serial dilutions of mAb starting at 1 μg/ml mAb were added. Anti-mouse 172 
or human IgG-HRP (GE Healthcare) followed by One-Step Ultra TMB EIA HRP 173 
substrate solution was used for detection. Positive reactivity is defined as a mean 174 
OD 450 nm >0.2 after background subtraction. Data represent the combination of 175 
three independent trials with each VLP run in duplicate in each trial. Sigmoidal 176 
dose response analysis was performed as previously described (14) using the 177 
reactivity at 1 ug/ml as 100% binding. EC50 values among VLPs were compared 178 
using One-way ANOVA with Dunnett’s post test. P<0.05 was considered 179 
significant.  VLPs with maximum reactivity below mean OD 450 nm 0.2 were 180 
assigned a value of zero for graphical representations. 181 
 182 
VLP-Carbohydrate Ligand-Binding Antibody Blockade Assays.   183 
Blockade assays using Pig Gastric Mucin Type III (Sigma Chemicals) were 184 
performed as previously described (14). PGM-bound VLPs were detected by 185 
rabbit anti-GII.4 norovirus polyclonal sera. The percent control binding was 186 
defined as the VLP-ligand binding level in the presence of test antibody or sera 187 
compared to the binding level in the absence of antibody multiplied by 100. All 188 
mAbs and sera were tested for blockade potential at two-fold serial dilutions 189 
ranging from 0.0039 to 2 μg/ml (mouse mAbs), 0.0039 to 16 μg/ml (human 190 
mAbs), and 0.0098 to 5% (mouse sera). Data from blockade experiments using 191 
monoclonal antibodies represent the combination of three independent trials with 192 
each VLP run in duplicate in each trial. Data from blockade experiments using 193 
polyclonal mouse sera represent the combination of two independent trials in 194 
which sera from five individual mice were tested for each VLP.  Sigmoidal dose 195 
response analysis was performed as previously described, and EC50 values 196 
among VLPs were compared using One-way ANOVA with Bonferroni post test. 197 
P<0.05 was considered significant. Blockade assays utilize VLP concentrations 198 
in the low nanomolar range; therefore, this assay does not discriminate between 199 
antibodies with sub-nanomolar affinities. 200 
 201 
Monoclonal antibodies and mouse polyclonal sera 202 
Mouse (12) and human (14) monoclonal antibodies were isolated as previously 203 
described.  Balb/c mice (five per group) were immunized by footpad injection with 204 
5 x 104 VRPs expressing norovirus capsid gene (GII.4-1987, GII.4-2002, GII.4-205 
2006b, GII.4-2009, P.D1, or P.D302).  Mice were boosted on day 21, euthanized 206 
7 days post-boost, and sera were harvested.  This study followed all institutional 207 
guidelines for animal care and experimentation (IACUC guidelines).  208 
 209 
Antigenic Cartography 210 
We utilized multi-dimensional scaling (MDS) approaches as described and 211 
implemented within the AntigenMap 3D software (39, 40).  The EC50 blockade 212 
titers of various sera against a panel of VLPs were normalized to maximum 213 
blockade titer of each sera, as well as to the maximum overall blockade titer 214 
across sera (Normalization method 1 in AntigenMap 3D).  Normalized values 215 
were used to calculate Euclidean distances, D, between each pair of VLPs.  For 216 
greater analytic, visualization, and graphical purposes, we then utilized 217 
Matlab8.1’s (MathWorks Inc, Natick, MA) cmdscale function to determine the 218 
XYZ coordinates such that the data can be displayed in 3 dimensions while 219 
maintaining the underlying Euclidean distances directly calculated from the data.  220 
We utilized R (www.r-project.org), with the package rgl for 3D visualization of 221 
these data.  We confirmed the output of our pipeline with that produced by 222 
AntigenMap 3D.223 
Results 224 
Comparison of sequence changes among chronic infection isolates GII.4-225 
2006b. 226 
Previous work has shown that changes identified in a few key surface 227 
exposed epitopes correlate with shifts in GII.4 norovirus antigenicity (11, 13-15), 228 
including residues in Epitope A (294, 296-298, 368, and 372) (13), Epitope D 229 
(393-395) (14), and Epitope E (407, 412-413) (15).  Changes in these residues 230 
likely alter the ability of preexisting immunity to neutralize the virus, selecting for 231 
the emergence of new epidemic strains.  232 
To study the within-host antigenic evolution of noroviruses during a 233 
chronic human infection, we aligned the sequence of the capsid P2 domains of 234 
GII.4-2006b, P.D1, and P.D302 to examine sequential amino acid changes from 235 
GII.4-2006b through P.D302 after at least 10 months of within-host evolution 236 
(23). Note that day 1 and day 302 refer to the days of sample collection and not 237 
from beginning of infection, as the time between the beginning of infection and 238 
the collection of the day 1 sample is unknown. Between VP1 amino acid 239 
positions 248-434, there are 9 differences between GII.4-2006b and P.D1. After 240 
10 months, there were 15 additional differences between P.D1 and P.D302, and 241 
20 differences between GII.4-2006b and P.D302 located between these amino 242 
acid positions (Figure 1A).  Similarly, there are 16 differences spanning this 243 
domain between GII.4-2006b and subsequent epidemic strains, GII.4-2009 and 244 
GII.4-2012.  Two of the differences between GII.4-2006b and P.D1 (S368A and 245 
S393G) and four of the differences between GII.4-2006b and P.D302 (A294G, 246 
S296T, S368A, and N412D) are located within blockade epitope sites (Figure 247 
1B). Four differences in blockade epitope residues also exist between P.D1 and 248 
P.D302 (A294G, S296T, G393S, N412D) (Figure 1B).  We synthesized GII.4-249 
2006b, P.D1, and P.D302 genes, expressed VLPs representing these strains, 250 
and measured differences in antigenicity and HBGA binding among the chronic 251 
infection isolates and GII.4-2006b using biological assays.  In addition, several 252 
amino acid substitutions present in the chronic infection strains that are 253 
conserved in past epidemic strains may also influence the antigenic and HBGA 254 
binding characteristics of epitope sites A (292, 295, 373), D (391), and E (414) 255 
(Figure 1B) based on their position relative to these epitopes in GII.4 homology 256 
models (Figure 1C).   257 
Comparison of HBGA binding in chronic infection isolates to GII.4-2006b.  258 
To evaluate differences in HBGA binding preferences among GII.4-2006b, 259 
P.D1, and P.D302, we measured VLP binding to synthetic biotinylated 260 
carbohydrates (A, B, Lea, Leb, Lex, Ley, H type 1, and H type 3).  As previously 261 
reported, GII.4-2006b bound A, B, Leb, Ley, and H type 3 (41).  In contrast, 262 
chronic infection strain VLPs exhibited differential HBGA binding profiles 263 
compared to GII.4-2006b and to each other (Table 1).  P.D1 was able to bind A, 264 
B, and H type 3, while P.D302 bound only B and H type 3 synthetic biotinylated 265 
HBGAs.  This indicates that HBGA binding preferences may be altered over time 266 
during chronic infection, perhaps influenced by individual within host HBGA 267 
expression phenotypes. 268 
 269 
Reactivity with GII.4 Mouse and Human mAbs 270 
To measure antigenic differences among VLPs representing GII.4-2006b 271 
and chronic strains P.D1 and P.D302, we performed enzyme-linked 272 
immunoassays (EIAs) using mouse and human mAbs.  We tested five GII.4-273 
2006b mouse mAbs (G2, G3, G4, G6, G7) and two GII.4 human mAbs (NVB111, 274 
NVB43.9), all of which target epitope site A residues (294, 296-298, 368, and 275 
372), for EIA binding with GII.4-2006b, P.D1, and P.D302 VLPs. GII.4-2006b and 276 
P.D1 differ in one epitope site A position, where P.D1 contains S368A compared 277 
to GII.4-2006b.  P.D302 is different from GII.4-2006b at 3/6 epitope site A 278 
residues: A294G, S296T, and S368A, while P.D1 and P.D302 are different at 2/6 279 
epitope site A residues: A294G and S296T.  We also tested reactivity of these 280 
VLPs with one human mAb (NVB97), which targets epitope site D residues (393-281 
395).  While GII.4-2006b and P.D302 share identical epitope site D residues, 282 
P.D1 has an S393G change compared to GII.4-2006b. We additionally tested 283 
one human mAb (NVB71.4) that targets an unmapped conserved GII.4 epitope 284 
(14). Consistent with previously-reported results, all mAbs reacted strongly with 285 
GII.4-2006b VLPs (12, 14) (Table 2). In contrast, EC50 values for P.D1 VLPs 286 
were significantly different (P<0.05) from GII.4-2006b VLPs for mouse mAbs G2, 287 
G4, G6, and human mAbs NVB43.9, and NVB111 (Table 2).  Moreover, EC50 288 
values for P.D302 VLPs were significantly different from GII.4-2006b for all mAbs 289 
except NVB71.4, and different from P.D1 VLPs for all but NVB71.4 and NVB111 290 
(Table 2). This indicates that epitope sites A and D are antigenically distinct 291 
among GII.4-2006b, P.D1, and P.D302, demonstrating antigenic variation over 292 
the course of chronic infection in important blockade epitopes.  293 
 294 
Blockade Activity for GII.4 Mouse and Human mAbs 295 
Compared to EIA, neutralization is a more relevant measure of functional 296 
antigenic change.  To test potential neutralization activity of mAbs (GII.4-2006b-297 
G2, G3, G4, G6, and G7, and NVB43.9, NVB71.4, NVB97, NVB111) against 298 
GII.4-2006b, P.D1, and P.D302 VLPs, we performed blockade assays, a 299 
correlate of protective immunity (42) and a neutralization surrogate. Consistent 300 
with previous findings, all mAbs were able to block ligand-VLP interactions for 301 
GII.4-2006b (12, 14) (Figure 2).  Likewise, P.D1 was blocked by all mAbs (Figure 302 
2). However, EC50 blockade titers for two out of five GII.4-2006b mouse mAbs, 303 
G2 (Figure 2A) and G7 (Figure 2E), and two of four GII.4 human mAbs, NVB111 304 
(Figure 2G) and NVB71.4 (Figure 2I), were significantly different, requiring 7.1X, 305 
2X, 2X, 3.2X more antibody, respectively, for blockade compared to GII.4-2006b 306 
VLPs.   P.D302 VLP-ligand binding was blocked by GII.4-2006b mouse mAbs G2 307 
(Figure 2A), G6 (Figure 2D), G7 (Figure 2E), but not by G3 (Figure 2B) or G4 308 
(Figure 2C), and blocked by GII.4 human mAb NVB71.4 (Figures 2I), but not by 309 
NVB43.9 (Figure 2F), NVB111 (Figure 2G), or NVB97 (Figures 2H).  EC50 310 
blockade titers were significantly different between GII.4-2006b and P.D302 for 311 
G2, G6, G7, and NVB71.4, requiring 12.6X, 15.9X, 12X, and 6.8X more mAb 312 
compared to GII.4-2006b, respectively.  Overall, EC50 blockade titers were 313 
significantly higher for P.D302 compared to both GII.4-2006 and P.D1 for all 314 
tested mAbs, demonstrating major antigenic changes in epitope sites A and D 315 
over the course of chronic norovirus infection. 316 
 317 
Blockade Response of Strain Specific Mouse Polyclonal Sera 318 
While monoclonal antibodies are informative of the changes in a single 319 
epitope, polyclonal sera are needed to evaluate global antigenic changes.  To 320 
measure differences in the total antibody response, we immunized mice with 321 
virus replicon particles (VRPs) expressing the capsid gene from GII.4-2006b, 322 
P.D1, and P.D302 or GII.4-2009, the consecutive outbreak strain following GII.4-323 
2006, and measured the induced serum blockade responses (Figure 3).  Mice 324 
immunized with GII.4-2006b VRPs mounted a robust blockade response against 325 
homotypic GII.4-2006b VLPs, while significantly more sera was needed to block 326 
GII.4-2009, P.D1, and P.D302 VLPs (16X, 9.4X, and 12.7X, respectively) (Figure 327 
3A).  Sera from mice immunized with GII.4-2009 VRPs induced a strong 328 
blockade response against GII.4-2009 VLPs; however, significantly more sera 329 
was needed to block GII.4-2006b and P.D302 VLPs, with 39X more sera needed 330 
to block P.D302 VLPs compared to GII.4-2009 (Figure 3B).  Sera from mice 331 
immunized with P.D1 VRPs most efficiently blocked homotypic P.D1 VLPs. EC50 332 
values indicated that more sera is required to block GII.4-2009 (3X) and P.D302 333 
(25.8X) than P.D1, while GII.4-2006b and P.D1 EC50 titers were not significantly 334 
different (Figure 3C). Sera from mice immunized with P.D302 VRPs efficiently 335 
blocked P.D302 VLP-ligand interactions and weakly blocked GII.4-2006b and 336 
P.D1, requiring 92X and 61X more sera, respectively.  P.D302 sera was unable 337 
to block GII.4-2009 VLPs (Figure 3D).  This data shows that chronic isolate VLPs 338 
induce antibody responses that are different from the parental strain and each 339 
other, demonstrating major changes in total antibody response over the course of 340 
chronic infection. 341 
 342 
Antigenic Cartography 343 
In order to further describe and visualize the differences between virus 344 
strains in their antigenic properties, we utilized the multi-dimensional scaling 345 
(MDS) approach known as antigenic cartography (39,40).  Specifically, we used 346 
the pipeline described in AntigenMap 3D (39) to measure and visualize the 347 
antigenic relationships among outbreak strains GII.4-1987, GII.4-1997, GII.4-348 
2002, GII.4-2006b, GII.4-2009, and GII.4-2012 as well as chronic isolates P.D1 349 
and P.D302, explicitly contrasting antigenic relationships between naturally 350 
occurring epidemic strains as well as intra-host variants. The antigenic distances 351 
between strains were measured using GII.4-1987, GII.4-2002, GII.4-2006b, 352 
GII.4-2009, P.D1, and P.D302 mouse sera EC50 blocking titers against VLPs 353 
representative of the specified GII.4 strains, and Euclidean distance values were 354 
calculated based on these titers (Figure 4A). Consistent with earlier findings (12), 355 
early (GII.4-1987, GII.4-1997, GII.4-2002) and late strains (GII.4-2006b, GII.4-356 
2009, GII.4-2012) formed distinct clusters (Figure 4B-C).  Not surprisingly, the 357 
early within host variant, P.D1, grouped closely with late strains (Figure 4B-C), 358 
reflecting its origins from the GII.4-2006b lineage.  In contrast, P.D302 did not 359 
group with any other strain and was antigenically distant from both the early and 360 
contemporary isolates. In order to confirm the visual analysis of these antigenic 361 
similarities, we compared Euclidean distances, D, between each pair of VLPs 362 
across all serum utilized for antigenic cartography (the Euclidean distance 363 
measures the straight-line distance between two points in a multidimensional 364 
space). We first examined the groupings of early and late GII.4 outbreak strains.  365 
The average distance within a group was 3.79 (range 2.11-6.39) while the 366 
average distance between early and contemporary clusters was 10.7 (range 367 
8.49-13.32), with each distance unit corresponding to a roughly 1.25-fold 368 
difference in blockade response between viruses (Figure 4A). As shown in 369 
Figures 4B and 4C, P.D1 grouped closely with late outbreak strain VLPs, with an 370 
average D of 3.46 (range 2.26-5.09) (Figure 4A). In contrast, P.D302 was quite 371 
distinct from both early and late outbreak strain viruses, as well as from P.D1, 372 
with an average D of 9.92 (range 8.73-11.62) (Figure 4A). During an ~10 month 373 
chronic infection in this individual, our data demonstrate that intra-host evolution 374 
can generate novel variants with unique HBGA binding patterns and encode 375 
unique antigenic differences that are as dramatically distinct as time-ordered, 376 
epidemic outbreak strains that emerge in human populations.   377 
 378 
Expansion of Epitope Site A 379 
We next determined whether novel sites of within host evolution can refine 380 
existing epitope maps and identify potential immunogenic changes in epidemic 381 
strains of the future. Amino acid position 373 exhibited a N373H change between 382 
P.D1 and P.D302 but was conserved in major GII.4 epidemic strains up until a 383 
N373R substitution emerged in GII.4-2012 Sydney. Although not supported with 384 
empirical data, recent work by Allen et al (43) suggests that this change in the 385 
Sydney strain may have impacted its emergence.  Since changes to 373 have 386 
never been shown to influence immunogenicity, and it is not included as a 387 
diagnostic A epitope site residue, this potentially hampers new epidemic strain 388 
identification. To determine whether position 373 contributes to antigenic 389 
differences in epitope A, we used the blockade assay to test potential 390 
neutralization of VLPs representing parental strains GII.4-2009 New Orleans, 391 
GII.4-2012 Sydney, and chimeric sequences GII.4-2012.09A, GII.4-392 
2012.09A.R373N, and GII.4-2012.R373N (Figure 5) by epitope A targeting 393 
human mAb 43.9. GII.4-2009 was efficiently blocked by mAb 43.9, while GII.4-394 
2012 required significantly more (55.3X) mAb for blockade.  Blockade response 395 
was partially restored in chimeras GII.4-2012.09A and GII.4-2012.R373N, but 396 
required 1.5X and 4.8X more mAb, respectively, for blockade compared to GII.4-397 
2009. EC50 blockade titers were not statically different between GII.4-398 
2012.09A.R373N and GII.4-2009 VLPs. Similar trends were seems using mouse 399 
mAbs targeting epitope A residues (data not shown).   400 
 401 
Discussion 402 
Noroviruses are an important cause of gastroenteritis in 403 
immunocompromised individuals (44, 45), who are at increased risk for severe 404 
disease outcomes (1, 44). Recent vaccine trials utilizing a VLP-based vaccine 405 
approach support the idea that efficacious vaccines can be generated that elicit 406 
short term protection in some healthy individuals, but vaccines may not protect 407 
immunocompromised populations, making development of therapeutics that 408 
effectively treat or prevent norovirus infections a top health priority. 409 
In immunocompetent people, norovirus infection results in acute disease 410 
outcomes (46). In contrast, immunocompromised individuals can develop 411 
symptomatic disease and high titer viral shedding up to years.  Unfortunately, the 412 
literature on specific chronically-infected norovirus patient populations is sparse, 413 
and duration and severity of chronic norovirus infections is likely influenced by 414 
several factors including underlying condition, drug treatment regime, degree of 415 
immunosuppression, and the rate of within host virus evolution, making it difficult 416 
to define the characteristics of a typical chronic norovirus case.  From these 417 
limited studies, it is difficult to discern whether there are characteristics of chronic 418 
norovirus infection that are broadly applicable to all populations, characteristics 419 
that are true to specific populations, or whether characteristics vary by each 420 
individual case.  Previous work has shown that during the course of chronic 421 
infection, virus genetic diversity can expand quickly (22, 23, 25, 35); however, it 422 
was previously unknown whether this genetic variation translated into antigenic 423 
variation or the emergence of antigenically unique isolates that differ significantly 424 
from contemporary epidemic strains. For the first time, our work clearly 425 
demonstrates the potential for significant antigenic variation over the course of 426 
chronic infection within an individual, which is important in terms of both 427 
therapeutic treatment considerations and for studying the potential role for 428 
chronic shedders as reservoirs for evolving new outbreak strains. 429 
Since there is no known animal reservoir for human noroviruses (47), the 430 
available data indicate that new GII.4 strains likely arise naturally within the 431 
human population by epochal evolution, immune driven selection, and inter-host 432 
transmission over time (12-14, 16, 17).  The occurrence of frequent long-term 433 
chronic infections in immunosuppressed patients also represents a possible 434 
source of new GII.4 norovirus strains with epidemic potential (23, 25, 35), as 435 
these patients may provide an appropriate environment for sustained immune-436 
directed molecular evolution by targeting previously identified surface exposed 437 
blockade epitopes for mutation driven escape.  Evidence supporting this 438 
hypothesis includes sequence data from chronically infected patients that 439 
demonstrate the emergence of genetic changes in GII.4 blockade epitopes that 440 
modulate inter-host antigenicity (22, 35). This diverse pool may contain variants 441 
antigenically distinct from the predominant circulating strain, allowing emergence 442 
of a new strain under the right conditions (25). However, host and environmental 443 
factors coupled with the type and degree of immunosuppression may affect the 444 
rate and complexity of intra-host evolution that occurs over time (23), and future 445 
work that evaluates the role of different immunosuppressive conditions on intra-446 
host norovirus evolution are needed.  447 
Our work demonstrated intra-host antigenic changes within epitope site A 448 
(amino acids 294, 296-298, 368, and 372). Interestingly, P.D302 contained 449 
residue substitutions in amino acid positions 292, 295, and 373, which are 450 
conserved in major GII.4 outbreak strains, except for 373, which was altered in 451 
the most recent predominant strain, GII.4-2012 Sydney. Changes in these 452 
residues likely impact epitope A antibody binding and blockade response either 453 
by altering the conformational landscape of the epitope or directly inhibiting the 454 
interaction of the antibody with the capsid. Using GII.4-2009/GII.4-2012 chimeric 455 
VLPs, we demonstrated that residues at position 373 impact the blockade 456 
response of human mAb NVB 43.9, an antibody that targets epitope A. This 457 
demonstrates that 373 is part of epitope A, expanding this epitope to 7 positions. 458 
Furthermore, we suggest that monitoring intra-host evolved strains may provide a 459 
novel diagnostic strategy to map key residues capable of mediating antigenic 460 
changes in future outbreaks. While positions 292 and 295 have been conserved 461 
in previous predominantly-circulating GII.4 strains, their ability to change in this 462 
patient and their proximity to known epitope A residues suggest that these 463 
residues could potentially impact antigenic change in epitope A in future 464 
epidemics, as residue 373 did in GII.4-2012 Sydney.  465 
Reactivity and blockade response data for antibody NVB97 demonstrates 466 
antigenic evolution in epitope site D during chronic infection.  Epitope site D 467 
minimally include residues 393-395, is in close proximity to the carbohydrate 468 
binding pocket (37), and previous work demonstrates that modulation of residues 469 
within this epitope modulate HBGA specificity (7).  Evolution in this epitope site is 470 
likely driven both by antibody selective pressure and pressure to maintain binding 471 
to one or more HBGAs.  Despite conservation of residues 393-395 between 472 
GII.4-2006b and P.D302, antigenic phenotypes differ significantly, demonstrating 473 
that NVB97 recognition is modulated by amino acid positions outside of the 474 
previously-defined epitope site D residues. Position 391, which is close to the 475 
carbohydrate binding pocket, is conserved in major outbreak strains and between 476 
GII.4-2006b and P.D1, and previous work demonstrated that an alanine 477 
substitution at this residue had little impact on HBGA binding (48). Neither the 478 
antigenic consequences of residue changes nor the impact of other residue 479 
substitutions on HBGA binding at this position have been rigorously evaluated, 480 
meaning that the D391N change in P.D302 may contribute to both the HBGA 481 
reactivity and antibody blockade differences observed for P.D302.  To explore 482 
this possibility, we created homology models of these P2 domains and compared 483 
the predicted polar interactions present in residues 390-395 (Figure 6) among 484 
GII.4-2006b, P.D1, and P.D302.  485 
Conformational comparisons between GII.4-2006b and P.D1 show 486 
general similarities in the shape created by residues 390-395, with exceptions 487 
being the loss of a side chain in 393 of P.D1, and slight shifts in position for side 488 
chains in residues 394 and 395 (Figure 6A and 6B). These conformational 489 
changes appear to impact the polar interactions within these residues, as the 490 
loss of the side chain in residue 393 ablates the hydrogen bond present in GII.4-491 
2006b.  In addition, the positional shifts in residues 394 and 395 in P.D1 appear 492 
to prevent formation of another hydrogen bond present in GII.4-2006b. 493 
Conformational comparisons between GII.4-2006b and P.D302 demonstrate that 494 
the residue change at 391 has significant impact on the shape and hydrogen 495 
bonding networks for residues 390-395 (Figures 6A and 6C).  In P.D302, position 496 
391 is bent downward, which differs from the position of this amino acid in GII.4-497 
2006b and P.D1.  The result of this change is the formation of a hydrogen bond 498 
between the side chain and main chain of 391. In addition, though residue 393 is 499 
conserved between GII.4-2006b and P.D302, the side chain is shifted downward 500 
in P.D302 compared to GII.4-2006b, shifting the position of the hydrogen bond 501 
found at this residue.  The formation of two additional novel hydrogen bonds 502 
between 390 & 393 and 390 & 395 suggests that the 391 residue change and 503 
resulting conformational changes allowed for these increased polar interactions. 504 
A slight conformational shift in residue 395 in P.D302 appears to ablate a polar 505 
interaction found in GII.4-2006b at this position. We also compared polar 506 
interactions of GII.4-2006, P.D1, and P.D302 to residues outside of 390-395 507 
(Figure 6D-F).  GII.4-2006b and P.D1 displayed five conserved polar interactions 508 
to surrounding amino acids (Figures 6D and 6E), while P.D302 lost the polar 509 
interaction at residue 391 and gained an additional bond at residue 394 (Figure 510 
6F).  511 
In addition to epitope site D being an antibody blockade epitope, these 512 
residues modulate HBGA binding, so evolution in this region is likely driven both 513 
by antibody selective pressure and pressure to maintain binding to one or more 514 
HBGAs.  Interestingly, all three structures maintained the two hydrogen bonds to 515 
positions 443 and 444. Residue 443 is in the HBGA binding site (37), and 516 
maintaining interaction with this residue may be selected for in this individual in 517 
order to retain HBGA binding. The altered HBGA binding profile and reduced 518 
NBV 97 binding and blockade for P.D302 may be explained by these polar 519 
differences, although this cannot be confirmed without a crystal structure of these 520 
P2 domains bound to NVB 97 and HBGAs. 521 
Our demonstration of intra-host changes in HBGA binding profiles in a 522 
chronically infected immunocompromised patient suggests that selection may 523 
favor variants that bind patient-specific HBGAs. While speculative, the potential 524 
emergence of intra-host variants that target patient-specific HBGA expression 525 
profiles could select for the emergence of novel strains that recognize unique or 526 
broad combinations of HBGA patterns, allowing for altered pathogenicity and 527 
transmission efficiencies in an individual or across select human populations. We 528 
could not evaluate this possibility in our study because the HBGA expression 529 
profile of this chronically infected patient is unknown. Future research could 530 
evaluate these HBGA phenotypic and FUT 2/3 genotypic relationships using 531 
saliva and cells from chronically infected patients.  532 
How much intra-host and inter-host antigenic variation is necessary to give 533 
rise to a new strain that could escape herd immunity in the general population?  534 
Using blockade EC50 data from mouse sera against GII.4-2006b, GII.4-2009 535 
(representative of a successive outbreak strain), P.D1, and P.D302, we 536 
demonstrate that the antigenic variation between P.D1 and P.D302 is 1.5X 537 
greater than that seen between GII.4-2006b and GII.4-2009.  To further address 538 
this question, we used antigenic cartography, which provides easily interpretable 539 
measures and visualization of multidimensional antigenic relationships, and has 540 
previously been used to study antigenic differences in influenza strains (40, 49).  541 
This analysis provided further support for the idea that within-host changes in the 542 
virus can equal or exceed those differences seen across successive outbreak 543 
strains, with the antigenic space between P.D302 and both GII.4-2006b (D=9.91) 544 
and P.D1 (D=9.15) being greater than the average between the consecutive 545 
outbreak strains used in this study (average D=4.98; range 2.11 to 12.11) and 546 
mirrors the global difference between early GII.4 isolates (1987, 1997, 2002) and 547 
contemporary strains (2006b, 2009, 2012).  548 
Antigenic cartography is a relatively new, powerful method with which to 549 
simply describe the multidimensional antigenic differences between virus strains. 550 
As such, there is room for improvement within these methods.  Indeed, more 551 
complex statistical models underlying antigenic cartography approaches are 552 
being developed to better account for uncertainty within these datasets (49), and 553 
more comprehensive surveys of both antisera and natural GII.4 isolates over a 554 
30-year time span will better allow for the characterization of antigenic change 555 
within noroviruses.  Within this study, the use of mouse sera permits us to use an 556 
immunologically clean background with no pre-exposure history and provides a 557 
clearer starting point to evaluate specific relationships among outbreak strains 558 
and the intra-host isolates. Future work will require well defined, time-ordered 559 
human sera during natural epidemic outbreaks, time-ordered sera during intra-560 
host chronic infections, and synthetic reconstruction of capsids representing both 561 
outbreak and unique panels of inter-host variants over time; unfortunately, to 562 
date, we have been unable to obtain the samples necessary to pursue this 563 
comprehensive investigation.  Our data suggest that intra-host evolution over a 564 
10-month period can yield sufficient antigenic change to escape existing herd 565 
immunity.  Clearly, additional work examining norovirus infectivity after prolonged 566 
shedding is needed in order to clarify whether chronically infected patients are a 567 
probable source of novel epidemic strains. 568 
Therapeutics are needed to alleviate clinical disease during long-term 569 
norovirus infection and prevent the potential emergence of novel antigenic 570 
variants with epidemic potential in the general population. Some success using 571 
IgG to treat chronic norovirus (32) coupled with our data demonstrating that P.D1 572 
is relatively antigenically similar to GII.4-2006b, while P.D302 is antigenically 573 
divergent, suggest that treating early during chronic infection may be important 574 
for viral clearance and also supports the possibility that similarly-administered 575 
broadly neutralizing antibodies may be viable treatment options for patients 576 
suffering from long-term norovirus infection.  Our work demonstrates that GII.4 577 
broadly-neutralizing mAb NVB71.4 retains blockade response against P.D1 and 578 
P.D302, even though both these strains are antigenically distinct from GII.4-579 
2006b, GII.4-2009, and presumably other major GII.4 strains.  This suggests that 580 
NVB71.4 or other antibodies with broad cross-blockade activity could be isolated 581 
and successfully used as norovirus therapeutics.  Importantly, different 582 
monoclonal antibodies will be needed that target other GI and GII strain chronic 583 
infections.  Furthermore, increased surveillance of norovirus isolates from 584 
chronically infected patients as well as deep sequencing of patient isolates 585 
should be considered in order to better understand the transmission dynamics 586 
and genetic potential of norovirus isolates from these patients since these are 587 
likely different from what is seen in the general population.  Overall, our work 588 
supports the idea that chronically infected individuals are potential reservoirs for 589 
antigenically novel norovirus strains, and further work to characterize their role in 590 
transmission and emergent norovirus outbreaks and development of therapeutics 591 
to combat chronic infections should receive a top priority. 592 
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 603 
Figure Legends 604 
Figure 1: Sequence Changes in Chronically Infected Patient Strains 605 
Compared to GII.4-2006b. 606 
(A) Available capsid amino acid sequences for GII.4-2006b, P.D1 and P.D302 607 
were aligned using Clustal Omega, and sequence differences among GII.4-2006, 608 
P.D1, and P.D302 are shown. GII.4-2006b residues are shown in purple. P.D1 609 
and P.D302 differences from GII.4-2006b are indicated in light blue, while orange 610 
indicates a reversion to the GII.4-2006b residues. (B) Alignment of GII.4-2006b, 611 
P.D1, and P.D302 amino acid sequences in and around Epitopes A, D, and E. 612 
Green indicates a position within a defined epitope, while white indicates nearby 613 
residues that may impact antigenicity in these epitopes. Yellow indicates an 614 
amino acid position newly defined as part of epitope A.  (C) Structural homology 615 
models of GII.4-2006b, P.D1, and P.D302 capsid P2 dimers shown from top 616 
view.  Purple shows location of Epitopes A, D, and E on the capsid P2 dimer, 617 
while green shows changing amino acid residues in P.D1 and P.D302 compared 618 
to GII.4-2006b.  619 
 620 
Table 1:  Chronic Infection Strain HBGA Binding Preferences 621 
VLPs representing GII.4-2006b, P.D1, and P.D302 were assayed for their ability 622 
to bind synthetic biotinylated HBGAs A, B, Lea, Leb, Lex, Ley, H type 1, and H 623 
type 3 by carbohydrate binding assay.  Positive reactivity was defined as a value 624 
greater or equal to 3X the background binding value. 625 
 626 
Table 2:  GII.4 Mouse and Human mAb EIA Reactivity with Chronic Infection 627 
Strains  628 
Mouse and human GII.4 monoclonal antibodies against were assayed for 629 
reactivity with GII.4-2006b, P.D1, and P.D302 VLPs by multiple dilution EIA. The 630 
mean percent binding (percent of the VLP bound to antibody in the dilution 631 
course compared to the amount of VLP bound with antibody at 1 ug/mL) of each 632 
VLP was fit with a sigmoidal curve, and the mean EC50 (μg/ml) EIA reactivity 633 
titers for GII.4-2006b, P.D1, and P.D302 were calculated. * Mean EC50 EIA 634 
reactivity titer for the test VLP is significantly different from the mean EC50 for 635 
GII.4-2006b (light grey), or ** was significantly different from both GII.4-2006b 636 
and P.D1 (p<0.05) (dark grey). Monoclonal antibodies that did not demonstrate 637 
EIA reactivity at or above OD450 nm 0.2 at 1 ug/mL with a particular VLP are 638 
denoted by an EC50 of >1 ug/mL. Statistics were calculated by One-way ANOVA 639 
with Bonferroni post test. 640 
 641 
Figure 2: GII.4 Mouse and Human mAb Blockade Response Against 642 
Chronic Infection Strains 643 
(A-I) Mouse and human GII.4 monoclonal antibodies were assayed for ability to 644 
block GII.4-2006b, P.D1, and P.D302 VLP interaction with carbohydrate ligand.  645 
The mean percent control binding (percent of the VLP bound to carbohydrate 646 
ligand in the presence of an antibody compared to the amount of VLP bound with 647 
no antibody present) of each VLP was fit with a sigmoidal curve, and the mean 648 
EC50 (μg/ml) blockade titers for GII.4-2006b, P.D1, and P.D302 were calculated. 649 
Error bars represent 95% confidence intervals. * Mean EC50 blockade titer for the 650 
test VLP is significantly different from the mean EC50 for GII.4-2006b (p<0.05), or 651 
** was significantly different from both GII.4-2006b and P.D1 (p<0.05). 652 
Monoclonal antibodies that did not block a particular VLP were assigned an EC50 653 
of 2X the upper limit of detection for statistical analysis and are shown on the 654 
graph by data points above the upper limit of detection (dashed line). Statistics 655 
were calculated by One-way ANOVA with Bonferroni post test. 656 
 657 
Figure 3:  Blockade Activity of Mouse Polyclonal Sera Against Homotypic 658 
and Heterotypic VLPs 659 
Mice were immunized with VRP expressing the capsid gene of GII.4-2006b, 660 
GII.4-2009, P.D1, and P.D302, and sera collected from these mice were tested 661 
for blockade activity against GII.4-2006b, GII.4-2009, P.D1, and P.D302 VLPs.  662 
(A) Blockade activity of sera from mice immunized against GII.4-2006b (A), GII.4-663 
2009 (B), P.D1 (C), and P.D302 (D) with homotypic and heterotypic VLPs. The 664 
mean percent control binding (percent of the VLP bound to carbohydrate ligand 665 
in the presence of sera compared to the amount of VLP bound with no sera 666 
present) of each VLP was fit with a sigmoidal curve, and the mean EC50 (% sera) 667 
blockade titers for GII.4-2006b, GII.4-2009, P.D1, and P.D302 were calculated. 668 
Error bars represent 95% confidence intervals. * Mean EC50 blockade titer for the 669 
test VLP is significantly different from the mean EC50 for the homotypic strain 670 
(p<0.05). Sera that did not block a particular VLP were assigned an EC50 of 10% 671 
sera for statistical analysis and are shown on the graph by data points above the 672 
upper limit of detection (dashed line). Statistics were calculated by One-way 673 
ANOVA with Bonferroni post test. 674 
 675 
Figure 4:  Antigenic Cartography for GII.4 Noroviruses 676 
Multidimentional Scaling (MDS) was used to identify the antigenic relationships 677 
between different norovirus strains.  A) Euclidean antigenic distances between 678 
virus strains were calculated based on the EC50 efficacy of antisera raised 679 
against GII.4-1987, GII.4-2002, GII.4-2006b, GII.4-2009, P.D1 and P.D302 VLPs.  680 
Green squares represent distances within either the early (1987, 1998 and 2002) 681 
or late (2006, 2009 and 2012) virus groups.  Purple squares show the distances 682 
between early and late virus groups.  (B-C) We determined XYZ-coordinates that 683 
maintain the underlying Euclidean distances between viruses, while illustrating 684 
the relationships between GII.4 norovirus strains, with each map-distance 685 
roughly corresponding to a ~1.25-fold change in blockade response.  B) Early 686 
strains GII.4-1987 (yellow), GII.4-1997 (red), and GII.4-2002 (light blue) grouped 687 
together (lower right hand group), and late strains GII.4-2006b (light purple), 688 
GII.4-2009 (dark blue), and GII.4-2012 (dark purple) grouped together (lower left 689 
hand group).  P.D1 grouped with late strains, closest to GII.4-2006b, while 690 
P.D302 was separate from either late or early strains (upper position).  C) Side 691 
view of the same 3D graph showing the antigenic differences between strains.  692 
 693 
Figure 5:  Expansion of Epitope Site A 694 
Epitope A targeting human GII.4 mAb 43.9 was assayed for its ability to block 695 
GII.4-2009 New Orleans, GII.4-2012 Sydney, GII.4-2012.09A, GII.4-2012.R373N, 696 
and GII.4-2012.09A.R373N VLP interaction with carbohydrate ligand. The mean 697 
percent control binding (percent of the VLP bound to carbohydrate ligand in the 698 
presence of an antibody compared to the amount of VLP bound with no antibody 699 
present) of each VLP was fit with a sigmoidal curve, and the mean EC50 (μg/ml) 700 
blockade titers for all VLPs were calculated. Error bars represent 95% confidence 701 
intervals.  Statistics were calculated by One-way ANOVA with Dunnett’s post 702 
test. * Mean EC50 blockade titer was significantly different from GII.4-2009.  703 
 704 
Figure 6:  Comparison of Epitope Site D Polar Interactions Among GII.4-705 
2006 and Chronic Infection Strains 706 
Pymol was used to model the polar interactions within residues 390-395 (A-C) 707 
and interactions between these residues and surrounding residues (D-F). GII.4-708 
2006b is shown in purple (A and D), P.D1 is shown in teal (B and E), and P.D302 709 
is shown in pink (C and F). Residues 390-395 are shown in orange for GII.4-710 
2006b, yellow for P.D1, and aqua for P.D302.  Dotted lines represent structure-711 
based predicted polar interactions. Dark purple residues represent positions that 712 
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Table	  1:	  	  Chronic	  Infec2on	  Strain	  HBGA	  Binding	  Preferences	  
VLPs	  represen*ng	  GII.4-­‐2006b,	  P.D1,	  and	  P.D302	  were	  assayed	  for	  their	  ability	  to	  bind	  
synthe*c	  bio*nylated	  HBGAs	  A,	  B,	  Lea,	  Leb,	  Lex,	  Ley,	  H	  type	  1,	  and	  H	  type	  3	  by	  
carbohydrate	  binding	  assay.	  	  Posi*ve	  reac*vity	  was	  deﬁned	  as	  a	  value	  greater	  or	  
equal	  to	  3X	  the	  background	  binding	  value.	  
2	  
Table	  2:	  	  GII.4	  Mouse	  and	  Human	  mAb	  EIA	  Reac9vity	  with	  Chronic	  Infec9on	  Strains	  	  
Mouse	  and	  human	  GII.4	  monoclonal	  an2bodies	  against	  were	  assayed	  for	  reac2vity	  
with	  GII.4-­‐2006b,	  P.D1,	  and	  P.D302	  VLPs	  by	  mul2ple	  dilu2on	  EIA.	  The	  mean	  percent	  
binding	  (percent	  of	  the	  VLP	  bound	  to	  an2body	  in	  the	  dilu2on	  course	  compared	  to	  the	  
amount	  of	  VLP	  bound	  with	  an2body	  at	  1	  ug/mL)	  of	  each	  VLP	  was	  ﬁt	  with	  a	  sigmoidal	  
curve,	  and	  the	  mean	  EC50	  (μg/ml)	  EIA	  reac2vity	  2ters	  for	  GII.4-­‐2006b,	  P.D1,	  and	  
P.D302	  were	  calculated.	  *	  Mean	  EC50	  EIA	  reac2vity	  2ter	  for	  the	  test	  VLP	  is	  signiﬁcantly	  
diﬀerent	  from	  the	  mean	  EC50	  for	  GII.4-­‐2006b	  (light	  grey),	  or	  **	  was	  signiﬁcantly	  
diﬀerent	  from	  both	  GII.4-­‐2006b	  and	  P.D1	  (p<0.05)	  (dark	  grey).	  Monoclonal	  an2bodies	  
that	  did	  not	  demonstrate	  EIA	  reac2vity	  at	  or	  above	  OD450	  nm	  0.2	  at	  1	  ug/mL	  with	  a	  
par2cular	  VLP	  are	  denoted	  by	  an	  EC50	  of	  >1	  ug/mL.	  Sta2s2cs	  were	  calculated	  by	  One-­‐
way	  ANOVA	  with	  Bonferroni	  post	  test.	  
3	  






